Liver cancer drug combination before surgery
Part of Cancer clinical trials.
This trial tests a combination of liver-directed chemotherapy (HAIC), two immunotherapy drugs (iparomlimab and tuvonralimab), and bevacizumab (a drug that blocks blood vessel growth) in people with liver cancer that is too large or numerous for immediate surgery but might become removable after treatment. The goal is to shrink the tumor enough to allow surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer that has not spread outside the liver.
- Your tumor is large (at least 5 cm) and you have 3 or fewer tumors, but doctors think it's not safe to remove them all right now.
- You have not had any previous drug treatment for your liver cancer (like chemo or immunotherapy).
- Your liver is working fairly well (Child-Pugh score A or low B).
- You are willing to use effective birth control during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs, TACE (a procedure to block blood flow to tumors), and lenvatinib (a targeted therapy) for people with liver cancer that has not responded to initial treatment. It aims to see if this combination can help shrink tumors or slow cancer growth.
This trial tests a treatment given before surgery to shrink liver cancer and improve outcomes. It combines a liver-directed therapy (HAIC) with two oral drugs (lenvatinib and a PD-1 inhibitor) for people with intermediate-stage liver cancer that can be removed surgically.
This trial tests if combining three therapies (sintilimab, lenvatinib, and HAIC) before surgery can help shrink liver tumors that are on the borderline of being removable. It's for people whose cancer has spread into nearby blood vessels but not to other organs.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (bevacizumab) after surgery or ablation for liver cancer that has a high chance of coming back. The goal is to see if this treatment can reduce the risk of recurrence.
This trial tests a combination of immunotherapy (camrelizumab), a targeted drug (rivoceranib), and liver-directed chemotherapy (HAIC) to shrink liver tumors enough to make them removable with surgery. It is for people with intermediate or advanced liver cancer that has not spread outside the liver.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus lenvatinib (a targeted therapy) given before surgery for hepatocellular carcinoma (a type of liver cancer). The goal is to see if this treatment can shrink tumors and reduce the chance of cancer coming back after surgery.
Hear when a new HCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.